紫杉醇涂层球囊对比普通球囊治疗CLTI膝下动脉病变的随机试验
单中心前瞻性1:1随机单盲优效性试验纳入64例CLTI患者、70条肢体、122处膝下动脉病变,比较紫杉醇DCB与普通球囊。
要点
- DCB组与普通球囊组12个月一期通畅率无显著差异(HR=0.64,p=0.24)。
- 慢性完全闭塞率DCB组81%、对照组89%,中位病变长度分别为150 mm和100 mm。
- 单中心随机试验未证实DCB在CLTI膝下动脉病变中优于普通球囊。
核心结论
- 在CLTI膝下动脉病变中,紫杉醇DCB相比普通球囊血管成形术未能在一期通畅率上显示优效性。
研究设计与样本
- 单中心前瞻性1:1随机、单盲、平行组、优效性试验(NCT02750605)。
- 共纳入64例CLTI患者、70条肢体、122处病变,每组35条肢体。
主要发现
- 两组人口学、合并症及Rutherford分级相似。
- DCB组与对照组慢性完全闭塞率分别为81%和89%(无显著差异),中位病变长度分别为150 mm和100 mm(无显著差异)。
临床怎么用
- 对于CLTI膝下动脉病变,现有证据未显示紫杉醇DCB在12个月一期通畅率上优于普通球囊,临床决策需结合个体情况。
局限性
- 单中心研究,样本量有限(64例患者、70条肢体)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Drug-coated balloons (DCB) might improve the results of below the knee (BTK) angioplasty, but sufficient randomized data comparing DCB and conventional angioplasty in treating patients with chronic limb threatening ischemia (CLTI) are lacking. This study aimed to perform a randomized comparison between a paclitaxel-coated angioplasty balloon catheter and a conventional balloon angioplasty catheter in treating BTK arterial lesions. DESIGN: A single-center prospective 1:1 randomized, single-blinded, parallel group, superiority trial. CLINICAL TRIAL REGISTRATION: NCT02750605. METHODS: Patients presenting with CLTI scheduled for endovascular treatment of BTK arterial lesions were assigned to DCB or conventional angioplasty. The primary endpoint was primary patency at 12 months. Secondary endpoints were target lesion revascularization (TLR), technical success, clinical success, amputation free survival (AFS), and serious adverse events. RESULTS: A total of 64 CLTI patients, 70 limbs, and 122 lesions were enrolled, with 35 limbs in each group. Demographics, comorbidities, and Rutherford class were similar in both treatment arms. The rates of chronic total occlusions were 81% and 89% (NS) in the DCB and control group, respectively, with corresponding median lesion lengths of 150 and 100 mm (NS) in the two groups. No significant differences were detected between groups regarding primary limb patency (hazard ratio [HR]=0.64, p=0.24, confidence interval [CI]=0.30-1.35). CONCLUSIONS: This single-center prospective randomized study could not demonstrate superiority of DCB compared with conventional balloon angioplasty regarding the primary endpoint, as primary patency, when treating BTK arterial lesions in patients with CLTI.Clinical ImpactThis randomised trial aims to pragmatically investigate whether there is a clinically relevant difference between drug eluting angioplasty and standard plain old balloon angioplasty in treating below the knee arterial lesions in subjects with chronic limb threatening ischemia. Regarding the primary endpoint variable, the study was not able to reveal a significant DCB superiority in primary patency.
引用
- Fransson T, Mohammed Y, Gottsäter A, et al. Prospective Randomized Clinical Trial Comparing Paclitaxel-Coated Balloon Versus Conventional Balloon Angioplasty in Treating Below the Knee Arterial Lesions in Chronic Limb Threatening Ischemia: The CRURAL DEB Study. J Endovasc Ther. 2025. PMID: 41263159. doi:10.1177/15266028251388746
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。